CVM News and Press, Cel-Sci Corporation

Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for Multikine® in the treatment of head and neck cancer in Saudi Arabia...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering pr...

U.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life Saudi partnership includes a 50%/50% net revenue share and suppor...

2026-06-15 04:59:26 ET CEL-SCI Corporation ( CVM ) slides 7.4% in premarket after pricing its "best-efforts" public offering of 2.5M shares of common stock at $1.00 per share.... Read the full article on Seeking Alpha For further details see: CEL-SCI slides a...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price of $1.00 per share. Total gross proceed...

Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies Strategic Agreement Marks Important Step Toward Commercialization of Multikine &#x...

2026-05-19 09:19:03 ET CEL-SCI Corporation (NYSE American: CVM) announced the closing of its best-efforts public offering of 6 million shares of common stock priced at $1.20 per share, resulting in gross proceeds of approximately $7.2 million before fees and expenses. The company sa...

2026-05-18 08:04:16 ET More on Cel-Sci Cel-Sci GAAP EPS of -$0.68 Historical earnings data for Cel-Sci Financial information for Cel-Sci Read the full article on Seeking Alpha For further details see: Cel-Sci GAAP EPS of -$1.35

On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia 50%/50% revenue sharing agreement for Multikine sales in Saudi Arabi...

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each share of common stock was sold at a publi...